Lessons learned from previous trials of bioresorbable vascular scaffolds (BVS) appear to have resulted in patient outcomes comparable to those in patients receiving metallic drug-eluting stents (DES). Excessive rates of adverse events driven by scaffold thrombosis have dogged previous studies of the BVS and led to the devices being taken off the market. However the ...
Bioresorbable scaffolds: not quite standing up to their promise
By Mardi Chapman
11 Oct 2018